| Assessment Status |
Rapid Review Complete |
| HTA ID |
25034b |
| Drug |
Selpercatinib |
| Brand |
Retsevmo® |
| Indication |
Selpercatinib (Retsevmo®) is indicated in adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate). |
| Rapid review commissioned |
15/05/2025 |
| Rapid review completed |
01/07/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of selpercatinib compared with the current standard of care. |
